BONE REGULATORY MECHANISMS DESTRUCTION IN EXPERIMENTAL CHRONIC KIDNEY DISEASE

Area of Science:

• Nephrology
• Endocrinology
• Immunology

Background:

• Chronic kidney disease (CKD) is associated with significant alterations in bone metabolism.
• Understanding the role of intercellular mediators in CKD-related bone remodeling is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of interleukin-1 receptor antagonist (IL-1 RA), interleukin-17 (IL-17), receptor activator of nuclear factor kB ligand (RANKL), and osteoprotegerin in the metabolic regulation of renal and bone tissue.
• To examine these mediators in the context of disrupted bone remodeling in a CKD model.

Main Methods:

• Animal model of chronic kidney disease (CKD).
• Serum analysis to quantify levels of IL-1 RA, IL-17, osteoprotegerin, and RANKL.
• Comparison of mediator levels between CKD and control groups.

Main Results:

• Significantly elevated serum levels of IL-1 RA, IL-17, osteoprotegerin, and RANKL were observed in animals with CKD-induced bone remodeling defects compared to controls.
• Specific increases noted: IL-1 RA (4.207 ± 0.546 pg/ml), IL-17 (33.944 ± 0.938 pg/ml), osteoprotegerin (28.338 ± 1.223 pg/ml), and RANKL (0.184 ± 0.018 pmol/l).
• These findings suggest a correlation between bone remodeling regulation and inflammation in CKD.

Conclusions:

• An imbalance between pro- and anti-inflammatory cytokines plays a significant role in both CKD development and bone remodeling processes.
• The investigated intercellular mediators are implicated in the metabolic dysregulation of renal and bone tissue in CKD.